他他多剂量滴定缓解慢性疼痛的药效学特性及影响因素。

IF 2.5 Q2 CLINICAL NEUROLOGY
Frontiers in pain research (Lausanne, Switzerland) Pub Date : 2025-01-17 eCollection Date: 2024-01-01 DOI:10.3389/fpain.2024.1474529
Liang Xin, Haoxiang Zhu, Suping Niu, Xie Han, Hongxian Pang, Jiangfan Li, Ye Hu, Xuhong Wang, Lujin Li, Yi Fang
{"title":"他他多剂量滴定缓解慢性疼痛的药效学特性及影响因素。","authors":"Liang Xin, Haoxiang Zhu, Suping Niu, Xie Han, Hongxian Pang, Jiangfan Li, Ye Hu, Xuhong Wang, Lujin Li, Yi Fang","doi":"10.3389/fpain.2024.1474529","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>The aim of this study was to establish a pharmacodynamic model of tapentadol analgesia under dose titration conditions, to quantitatively analyze the time-effect relationship of the drug, and to identify relevant influencing factors. This model is intended to provide a pharmacodynamic reference for designing rational tapentadol dose titration schemes in clinical research.</p><p><strong>Methods: </strong>Randomized controlled trials assessing the efficacy of tapentadol in the management of chronic pain were retrieved from public databases (PubMed and EMBASE). A time-effect relationship model of the percent change in Numerical Rating Scale (NRS) scores post-tapentadol intervention from baseline was constructed, along with a covariate model to identify factors significantly impacting the analgesic effects of tapentadol. Potential influencing factors that were clinically significant but not included in the final covariate model were examined for their impact trends on tapentadol analgesia through subgroup analysis.</p><p><strong>Results: </strong>A total of 16 studies involving 4,508 participants were included in the analysis. Covariate analysis indicated that age significantly affected the maximum reduction in NRS scores following tapentadol treatment, with the reduction rate being 40.9% for patients aged 45 and 60.7% for those aged 65, suggesting that older patients have a higher demand for pain relief. Furthermore, studies published after 2014 and placebo-controlled trials showed a slower rate of NRS reduction, indicating a more cautious approach to tapentadol dosing titration post the U.S. opioid crisis and in placebo-controlled contexts. Additionally, subgroup analysis suggested that higher titration doses, higher baseline NRS levels, the use of extended-release tapentadol, and a smaller proportion of male participants were trends associated with better analgesic effects, although the differences were not statistically significant. Moreover, the study found that tapentadol was significantly more effective in treating lower back pain compared to non-lower back pain.</p><p><strong>Conclusion: </strong>This research successfully developed a pharmacodynamic model for dose-titrated tapentadol administration, which can simulate the temporal changes in analgesic effects of tapentadol across different clinical scenarios. This model can guide the formulation of dosing titration protocols for tapentadol in clinical research.</p><p><strong>Systematic review registration: </strong>https://inplasy.com/inplasy-2024-5-0014/.</p>","PeriodicalId":73097,"journal":{"name":"Frontiers in pain research (Lausanne, Switzerland)","volume":"5 ","pages":"1474529"},"PeriodicalIF":2.5000,"publicationDate":"2025-01-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11782195/pdf/","citationCount":"0","resultStr":"{\"title\":\"Pharmacodynamic characteristics and influencing factors of tapentadol for chronic pain relief under dose titration.\",\"authors\":\"Liang Xin, Haoxiang Zhu, Suping Niu, Xie Han, Hongxian Pang, Jiangfan Li, Ye Hu, Xuhong Wang, Lujin Li, Yi Fang\",\"doi\":\"10.3389/fpain.2024.1474529\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objective: </strong>The aim of this study was to establish a pharmacodynamic model of tapentadol analgesia under dose titration conditions, to quantitatively analyze the time-effect relationship of the drug, and to identify relevant influencing factors. This model is intended to provide a pharmacodynamic reference for designing rational tapentadol dose titration schemes in clinical research.</p><p><strong>Methods: </strong>Randomized controlled trials assessing the efficacy of tapentadol in the management of chronic pain were retrieved from public databases (PubMed and EMBASE). A time-effect relationship model of the percent change in Numerical Rating Scale (NRS) scores post-tapentadol intervention from baseline was constructed, along with a covariate model to identify factors significantly impacting the analgesic effects of tapentadol. Potential influencing factors that were clinically significant but not included in the final covariate model were examined for their impact trends on tapentadol analgesia through subgroup analysis.</p><p><strong>Results: </strong>A total of 16 studies involving 4,508 participants were included in the analysis. Covariate analysis indicated that age significantly affected the maximum reduction in NRS scores following tapentadol treatment, with the reduction rate being 40.9% for patients aged 45 and 60.7% for those aged 65, suggesting that older patients have a higher demand for pain relief. Furthermore, studies published after 2014 and placebo-controlled trials showed a slower rate of NRS reduction, indicating a more cautious approach to tapentadol dosing titration post the U.S. opioid crisis and in placebo-controlled contexts. Additionally, subgroup analysis suggested that higher titration doses, higher baseline NRS levels, the use of extended-release tapentadol, and a smaller proportion of male participants were trends associated with better analgesic effects, although the differences were not statistically significant. Moreover, the study found that tapentadol was significantly more effective in treating lower back pain compared to non-lower back pain.</p><p><strong>Conclusion: </strong>This research successfully developed a pharmacodynamic model for dose-titrated tapentadol administration, which can simulate the temporal changes in analgesic effects of tapentadol across different clinical scenarios. This model can guide the formulation of dosing titration protocols for tapentadol in clinical research.</p><p><strong>Systematic review registration: </strong>https://inplasy.com/inplasy-2024-5-0014/.</p>\",\"PeriodicalId\":73097,\"journal\":{\"name\":\"Frontiers in pain research (Lausanne, Switzerland)\",\"volume\":\"5 \",\"pages\":\"1474529\"},\"PeriodicalIF\":2.5000,\"publicationDate\":\"2025-01-17\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11782195/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Frontiers in pain research (Lausanne, Switzerland)\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.3389/fpain.2024.1474529\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q2\",\"JCRName\":\"CLINICAL NEUROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Frontiers in pain research (Lausanne, Switzerland)","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3389/fpain.2024.1474529","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0

摘要

目的:建立剂量滴定条件下他他多镇痛的药效学模型,定量分析药物的时效关系,并确定相关影响因素。该模型旨在为临床研究设计合理的他他多剂量滴定方案提供药效学参考。方法:从公共数据库(PubMed和EMBASE)中检索评估他他多治疗慢性疼痛疗效的随机对照试验。构建他他多干预后数值评定量表(NRS)评分较基线变化百分比的时效关系模型,并建立协变量模型以确定影响他他多镇痛效果的显著因素。通过亚组分析,检验临床显著但未纳入最终协变量模型的潜在影响因素对他他多镇痛的影响趋势。结果:共纳入16项研究,涉及4508名受试者。协变量分析显示,年龄显著影响他他多治疗后NRS评分的最大降幅,45岁患者的降幅为40.9%,65岁患者的降幅为60.7%,说明老年患者对缓解疼痛的需求更高。此外,2014年之后发表的研究和安慰剂对照试验显示,NRS下降速度较慢,这表明在美国阿片类药物危机后和安慰剂对照背景下,他他多剂量滴定的方法更加谨慎。此外,亚组分析表明,较高的滴定剂量、较高的基线NRS水平、使用缓释他他多以及较小比例的男性参与者与更好的镇痛效果相关,尽管差异无统计学意义。此外,研究发现,与非腰痛相比,他他多在治疗腰痛方面明显更有效。结论:本研究成功建立了他他多剂量滴定给药的药效学模型,可以模拟不同临床情景下他他多镇痛作用的时间变化。该模型可指导临床研究中他他多剂量滴定方案的制定。系统评审注册:https://inplasy.com/inplasy-2024-5-0014/。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Pharmacodynamic characteristics and influencing factors of tapentadol for chronic pain relief under dose titration.

Objective: The aim of this study was to establish a pharmacodynamic model of tapentadol analgesia under dose titration conditions, to quantitatively analyze the time-effect relationship of the drug, and to identify relevant influencing factors. This model is intended to provide a pharmacodynamic reference for designing rational tapentadol dose titration schemes in clinical research.

Methods: Randomized controlled trials assessing the efficacy of tapentadol in the management of chronic pain were retrieved from public databases (PubMed and EMBASE). A time-effect relationship model of the percent change in Numerical Rating Scale (NRS) scores post-tapentadol intervention from baseline was constructed, along with a covariate model to identify factors significantly impacting the analgesic effects of tapentadol. Potential influencing factors that were clinically significant but not included in the final covariate model were examined for their impact trends on tapentadol analgesia through subgroup analysis.

Results: A total of 16 studies involving 4,508 participants were included in the analysis. Covariate analysis indicated that age significantly affected the maximum reduction in NRS scores following tapentadol treatment, with the reduction rate being 40.9% for patients aged 45 and 60.7% for those aged 65, suggesting that older patients have a higher demand for pain relief. Furthermore, studies published after 2014 and placebo-controlled trials showed a slower rate of NRS reduction, indicating a more cautious approach to tapentadol dosing titration post the U.S. opioid crisis and in placebo-controlled contexts. Additionally, subgroup analysis suggested that higher titration doses, higher baseline NRS levels, the use of extended-release tapentadol, and a smaller proportion of male participants were trends associated with better analgesic effects, although the differences were not statistically significant. Moreover, the study found that tapentadol was significantly more effective in treating lower back pain compared to non-lower back pain.

Conclusion: This research successfully developed a pharmacodynamic model for dose-titrated tapentadol administration, which can simulate the temporal changes in analgesic effects of tapentadol across different clinical scenarios. This model can guide the formulation of dosing titration protocols for tapentadol in clinical research.

Systematic review registration: https://inplasy.com/inplasy-2024-5-0014/.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
2.10
自引率
0.00%
发文量
0
审稿时长
13 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信